Cyclolavandulyl diphosphate synthase, which catalyzes both the condensation of two molecules of C5 dimethylallyl diphosphate and the subsequent cyclization, has been crystallized and X-ray diffraction data have been collected and analyzed.
Keywords: condensing enzyme, cyclase, cyclolavandulyl diphosphate synthase, Streptomyces sp. CL190, terpene
Abstract
Cyclolavandulyl diphosphate synthase (CLDS; estimated molecular weight 23.1 kDa) from the soil bacterium Streptomyces sp. CL190 is an enzyme that catalyzes both the condensation of two molecules of C5 dimethylallyl diphosphate (DMAPP) and the subsequent cyclization. CLDS was crystallized in the absence and the presence of the substrate DMAPP. Diffraction data were collected at a synchrotron source and the crystals diffracted to 2.00 and 1.73 Å resolution, respectively. The crystal obtained in the absence of DMAPP belonged to space group P212121, with unit-cell parameters a = 39.0, b = 87.5, c = 113.6 Å. The crystal obtained in the presence of DMAPP belonged to space group P1, with unit-cell parameters a = 46.9, b = 61.7, c = 82.2 Å, α = 74.0, β = 84.5, γ = 86.0°.
1. Introduction
Terpenoids represent an important class of biologically active compounds owing to their structural diversity (Maimone & Baran, 2007 ▶; Sacchettini & Poulter, 1997 ▶). Over the past several decades, various studies have sought to identify the biosynthetic mechanisms responsible for terpenoid complexity (Christianson, 2006 ▶). The complexity of the terpenoid skeleton arises from the condensation of C5 isoprene units and a subsequent cyclization. Typically, these condensation and cyclization reactions are independently catalyzed by isoprenyl diphosphate synthase (IDS) and terpene cyclase, respectively.
Cyclolavandulyl diphosphate (CLDP) is a C10 monoterpene with a branched and cyclized carbon skeleton (Fig. 1 ▶). The skeleton is found in some natural products derived from plants and bacteria. Although the cyclolavandulyl skeleton was discovered in nature approximately half a century ago (Logani et al., 1967 ▶), the enzyme responsible for synthesizing this skeleton remained largely unknown. Recently, we identified and characterized CLDP synthase (CLDS) from the soil bacterium Streptomyces sp. CL190 (Ozaki et al., 2014 ▶); this bacterium produces lavanducyanin, which is a phenazine with an N-linked cyclolavandulyl structure (Imai et al., 1989 ▶). CLDS is a single-domain enzyme consisting of only 217 residues and catalyzes both the condensation of two molecules of C5 dimethylallyl diphosphate (DMAPP) and the subsequent cyclization to form CLDP (Fig. 1 ▶).
Figure 1.

Proposed reaction mechanism for CLDS. LDP, lavandulyl diphosphate.
CLDS belongs to the cis-IDS superfamily. Undecaprenyl diphosphate synthase (UPPS), which is also a member of this family, catalyzes the sequential cis condensations of eight C5 isopentenyl diphosphates with a C15 trans,trans-farnesyl diphosphate to produce the acyclic C55 undecaprenyl diphosphate, which is indispensable for peptidoglycan biosynthesis in the bacterial cell wall. The crystal structures of UPPS from Micrococcus luteus and Escherichia coli have previously been determined, and the structural features necessary for the condensation reaction have been clarified (PDB entries 1f75, 1ueh and 1x09; Fujihashi et al., 2001 ▶; Chang et al., 2003 ▶; Guo et al., 2005 ▶). The structures enabled the identification of the amino-acid residues that recognize the phosphate moiety of the isoprenyl diphosphate substrates. A comparison of the amino-acid sequences of CLDS and UPPS revealed that these residues are highly conserved between CLDS and UPPS (Ozaki et al., 2014 ▶). However, because the dual nature of the CLDS activity is unique within the cis-IDS superfamily, the determination of the crystal structure of CLDS is necessary to elucidate the structural basis for this unique CLDS-catalyzed reaction.
To understand the structural basis for this unusual two-step CLDS-catalyzed reaction, we crystallized CLDS and collected and analyzed X-ray diffraction data from the CLDS crystals.
2. Materials and methods
2.1. Overexpression and purification
The previously described expression plasmid pH8CLDS (Ozaki et al., 2014 ▶) was used to express CLDS with an N-terminal eight-histidine tag (CLDS-NH) in E. coli BL21-CodonPlus(DE3)-RIL cells. To express CLDS with a C-terminal six-histidine tag (CLDS-CH), we constructed the expression plasmid as described below. The clds gene encoding CLDS (accession No. AB872045) from Streptomyces sp. CL190 was amplified by polymerase chain reaction using two oligonucleotides (Table 1 ▶). The amplified DNA fragment encoding CLDS with a C-terminal (His)6 tag was cloned into the EcoRI/HindIII sites of the pBluescript II SK(+) vector. After verifying the nucleotide sequence, the DNA fragment was cloned into the NdeI/HindIII sites of the pET-26b(+) vector to construct the plasmid pET-CLDS-CH, which was transformed into E. coli BL21-CodonPlus(DE3)-RIL cells.
Table 1. Overexpression information.
| CLDS-NH | CLDS-CH | |
|---|---|---|
| Source organism | Streptomyces sp. CL190 | Streptomyces sp. CL190 |
| DNA source | gDNA (accession No. AB872045) | pH8CLDS (Ozaki et al., 2014 ▶) |
| Forward primer | 5-GGGGGATCCACCACGTTGATGCTGCTGCCG-3 | 5-GGGGAATTCCATATGACCACGTTGATGCTGCTG-3 |
| Reverse primer | 5-GGAAGCTTTCACGCCGGGTAGCCGCCGAAG-3 | 5-CCCCAAGCTTTTAGTGATGGTGATGGTGATGCGCCGGGTAGCCGCCGAA-3 |
| Cloning vector | pt7blue t-vector | pBluescript II SK(+) |
| Expression vector | pHIS8 (Jez et al., 2000 ▶) | pET-26b(+) |
| Expression plasmid | pH8CLDS (Ozaki et al., 2014 ▶) | pET-CLDS-CH |
| Expression host | E. coli BL21-CodonPlus(DE3)-RIL | E. coli BL21-CodonPlus(DE3)-RIL |
| Complete amino-acid sequence of the construct produced | MKHHHHHHHHGGLVPRGSHGGSTTLMLLPDGMRRWSEKNGVSLDDGYAAMGDKIIEFMGWAKEEGVKTLYITASSAANHGRPEAAVNTFMEAFTEVIRRCHSQFKFDFSGSLDLVSEDYLTELSALRDKSDSESDFTLHYILGMSLSHEVVGIFNKLNGKIPEMTEEILAENAYVPTQVDYIIRTGGAIRMSSFFPLMSPYAELHFSPVLFPDTTRADFDAALKDLRARDRRFGGYPA | MTTLMLLPDGMRRWSEKNGVSLDDGYAAMGDKIIEFMGWAKEEGVKTLYITASSAANHGRPEAAVNTFMEAFTEVIRRCHSQFKFDFSGSLDLVSEDYLTELSALRDKSDSESDFTLHYILGMSLSHEVVGIFNKLNGKIPEMTEEILAENAYVPTQVDYIIRTGGAIRMSSFFPLMSPYAELHFSPVLFPDTTRADFDAALKDLRARDRRFGGYPAHHHHHH |
The cells harbouring pH8CLDS or pET-CLDS-CH were grown in 2×YT broth in the presence of kanamycin (50 µg ml−1) and chloramphenicol (30 µg ml−1) at 303 K. When the optical density at 600 nm of the culture reached approximately 0.6, protein expression was induced by the addition of 0.1 mM isopropyl β-d-1-thiogalactopyranoside and the culture was incubated at 303 K for an additional 12 h. The cells were harvested, washed in buffer A (20 mM Tris–HCl pH 8.0) and resuspended in this buffer. The resuspended cells were lysed by sonication and centrifuged at 40 000g for 20 min. The supernatant was applied onto an Ni2+-affinity column (Novagen) equilibrated with buffer B (20 mM Tris–HCl pH 8.0, 150 mM NaCl) containing 20 mM imidazole, followed by successive washing with this buffer. Proteins bound to the resin were eluted with buffer B containing 500 mM imidazole. The fractions containing the histidine-tagged CLDS were concentrated by ultrafiltration using Vivaspin 20 concentrators (10 kDa molecular-weight cutoff; Sartorius Stedim Biotech). The concentrated sample was applied onto a HiLoad 26/60 Superdex 75 (GE Healthcare) size-exclusion column that was equilibrated with buffer B, and fractions were collected every 2.5 ml at a flow rate of 2.5 ml min−1. The oligomeric state of the protein was estimated to be a dimer based on the elution volume from size-exclusion chromatography. The purity of the purified CLDS was greater than 95%, as verified by SDS–PAGE (Supplementary Figs. S1 and S21). Greater than 40 mg of CLDS-NH and CLDS-CH was purified from 1.6 l of culture, and the proteins were used for crystallization without removal of the tags.
2.2. Crystallization
Crystallization conditions were screened by the hanging-drop vapour-diffusion method using Crystal Screen (Hampton Research) and the Wizard crystallization screen series (Emerald Bio). The screens were set up using 2 µl drops consisting of 1 µl reservoir solution and 1 µl 10 mg ml−1 CLDS solution with and without 5 mM DMAPP and 2 mM MgSO4 (Table 2 ▶).
Table 2. Crystallization.
| CLDS-NH | CLDS-CH | |
|---|---|---|
| Method | Hanging-drop vapour diffusion | Hanging-drop vapour diffusion |
| Plate type | 24-well VDX plate (Hampton Research) | 24-well VDX plate (Hampton Research) |
| Temperature (K) | 293 | 293 |
| Protein concentration (mgml1) | 10 | 10 |
| Buffer composition of protein solution | 20mM TrisHCl pH 8.0, 150mM NaCl, 5mM DMAPP, 2mM MgSO4 | 20mM TrisHCl pH 8.0, 150mM NaCl |
| Composition of reservoir solution | 100mM HEPESNaOH pH 7.0, 24% PEG 2000 | 100mM TrisHCl pH 7.0, 1M sodium citrate tribasic, 200mM NaCl |
| Volume and ratio of drop | 2l, 1:1 protein:reservoir solution | 2l, 1:1 protein:reservoir solution |
| Volume of reservoir (l) | 500 | 500 |
2.3. Data collection and processing
Prior to data collection from the CLDS-NH–DMAPP–MgSO4 crystal, the crystal was directly flash-cooled in a nitrogen-gas stream at 95 K because it was unstable in cryoprotectant buffer containing PEG 400. Prior to data collection of CLDS-CH, the crystal was briefly soaked in a cryoprotectant solution consisting of 100 mM Tris–HCl pH 7.0, 1 M sodium citrate tribasic, 200 mM sodium chloride, 30%(v/v) glycerol and then flash-cooled in a nitrogen-gas stream at 95 K. Diffraction data (λ = 1.0 Å) for CLDS-NH–DMAPP–MgSO4 and CLDS-CH were collected using charge-coupled device detectors (ADSC Quantum 315r and ADSC Quantum 270) at the BL-5A and AR-NE3A stations of the Photon Factory, High Energy Accelerator Research Organization (KEK), Tsukuba, Japan, respectively (Table 3 ▶). Diffraction images (Supplementary Figs. S1 and S2) were indexed and scaled using HKL-2000 (Otwinowski & Minor, 1997 ▶). Molecular replacement was performed with Phaser (McCoy et al., 2007 ▶) in the CCP4 program suite (Winn et al., 2011 ▶).
Table 3. Data collection and processing.
Values in parentheses are for the outer shell.
| CLDS-NHDMAPPMgSO4 | CLDS-CH | |
|---|---|---|
| Beamline | BL-5A, PF, KEK | AR-NE3A, PF, KEK |
| Wavelength () | 1.0 | 1.0 |
| Temperature (K) | 95 | 95 |
| Detector | ADSC Quantum 315r CCD | ADSC Quantum 270 CCD |
| Crystal-to-detector distance (mm) | 214 | 229 |
| Rotation range per image () | 1.0 | 1.0 |
| Total rotation range () | 180 | 180 |
| Exposure time per image (s) | 0.9 | 1.0 |
| Space group | P1 | P212121 |
| a, b, c () | 46.9, 61.7, 82.2 | 39.0, 87.5, 113.6 |
| , , () | 74.0, 84.5, 86.0 | 90, 90, 90 |
| Resolution range () | 501.73 (1.761.73) | 502.00 (2.032.00) |
| Total No. of reflections | 154893 | 189589 |
| No. of unique reflections | 92115 | 27009 |
| Completeness (%) | 85.9 (95.5)† | 99.7 (100.0) |
| Multiplicity | 2.0 (2.0) | 7.0 (7.3) |
| I/(I) | 18.1 (1.8) | 21.8 (3.2) |
| R r.i.m. | 0.083 (0.434) | 0.117 (0.521) |
Owing to the ice rings observed in the diffraction image (Supplementary Fig. S1).
3. Results and discussion
Crystals of CLDS-NH appeared in a droplet containing 100 mM HEPES–NaOH pH 7.0, 24% PEG 2000 in the presence of 5 mM DMAPP and 2 mM MgSO4 (Fig. 2 ▶). Crystals of CLDS-CH appeared in a droplet containing 100 mM Tris–HCl pH 7.0, 1 M sodium citrate tribasic, 200 mM sodium chloride (Fig. 3 ▶). X-ray diffraction data from these CLDS crystals were collected and analyzed. Details of the data-collection statistics are summarized in Table 3 ▶. The crystal obtained in the presence of DMAPP belonged to space group P1, with unit-cell parameters a = 46.9, b = 61.7, c = 82.2 Å, α = 74.0, β = 84.5, γ = 86.0°. The crystal obtained in the absence of DMAPP belonged to space group P212121, with unit-cell parameters a = 39.0, b = 87.5, c = 113.6 Å. We attempted molecular replacement with UPPS from Campylobacter jejuni (26% identity; PDB entry 3ugs; Center for Structural Genomics of Infectious Diseases, unpublished work), UPPS from E. coli (27% identity; PDB entry 1ueh; Chang et al., 2003 ▶) and UPPS from Helicobacter pylori (27% identity; PDB entry 2d2r; Kuo et al., 2008 ▶) as search models. However, this attempt did not provide a possible solution. Therefore, we are now trying to determine the three-dimensional structure of CLDS by the multiwavelength anomalous diffraction method. These preliminary results will enable the elucidation of the structural basis of the unique CLDS activity.
Figure 2.

Crystal of CLDS-NH in the presence of DMAPP and MgSO4.
Figure 3.

Crystal of CLDS-CH.
Supplementary Material
Supporting Information.. DOI: 10.1107/S2053230X14018883/us5062sup1.pdf
Acknowledgments
We acknowledge support from a Grant-in-Aid for Scientific Research (B) (26292058 to TK) from the Japan Society for the Promotion of Sciences. This work was performed under the approval of the Photon Factory Program Advisory Committee (proposal Nos. 2012G019 and 2014G106).
Footnotes
Supporting information has been deposited in the IUCr electronic archive (Reference: US5062).
References
- Chang, S.-Y., Ko, T.-P., Liang, P.-H. & Wang, A. H.-J. (2003). J. Biol. Chem. 278, 29298–29307. [DOI] [PubMed]
- Christianson, D. W. (2006). Chem. Rev. 106, 3412–3442. [DOI] [PubMed]
- Fujihashi, M., Zhang, Y.-W., Higuchi, Y., Li, X.-Y., Koyama, T. & Miki, K. (2001). Proc. Natl Acad. Sci. USA, 98, 4337–4342. [DOI] [PMC free article] [PubMed]
- Guo, R.-T., Ko, T.-P., Chen, A. P.-C., Kuo, C.-J., Wang, A. H.-J. & Liang, P.-H. (2005). J. Biol. Chem. 280, 20762–20774. [DOI] [PubMed]
- Imai, S., Furihata, K., Hayakawa, Y., Noguchi, T. & Seto, H. (1989). J. Antibiot. 42, 1196–1198. [DOI] [PubMed]
- Jez, J. M., Ferrer, J.-L., Bowman, M. E., Dixon, R. A. & Noel, J. P. (2000). Biochemistry, 39, 890–902. [DOI] [PubMed]
- Kuo, C.-J., Guo, R.-T., Lu, I.-L., Liu, H.-G., Wu, S.-Y., Ko, T.-P., Wang, A. H.-J. & Liang, P.-H. (2008). J. Biomed. Biotechnol. 2008, 841312. [DOI] [PMC free article] [PubMed]
- Logani, M. K., Varshney, I. P., Pandey, R. C. & Dev, S. (1967). Tetrahedron Lett. 28, 2645–2648.
- Maimone, T. J. & Baran, P. S. (2007). Nature Chem. Biol. 3, 396–407. [DOI] [PubMed]
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Ozaki, T., Zhao, P., Shinada, T., Nishiyama, M. & Kuzuyama, T. (2014). J. Am. Chem. Soc. 136, 4837–4840. [DOI] [PubMed]
- Sacchettini, J. C. & Poulter, C. D. (1997). Science, 277, 1788–1789. [DOI] [PubMed]
- Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting Information.. DOI: 10.1107/S2053230X14018883/us5062sup1.pdf
